Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Context Therapeutics ( (CNTX) ) is now available.
On April 2, 2026, Context Therapeutics announced that the U.S. Food and Drug Administration granted Fast Track designation to CTIM-76, its investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for patients with platinum-resistant ovarian cancer who have exhausted standard therapies. The designation is intended to expedite development of CTIM-76 to address this high unmet medical need segment in ovarian cancer.
CTIM-76 is currently being evaluated in an ongoing Phase 1 clinical trial for CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers, with the study assessing safety, tolerability, pharmacokinetics and anti-tumor activity. Context indicated that interim Phase 1a data are expected in June 2026, and the Fast Track status may streamline regulatory interactions and potentially accelerate CTIM-76’s path through clinical development, which could be significant for patients and the company’s oncology pipeline.
The most recent analyst rating on (CNTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.
Spark’s Take on CNTX Stock
According to Spark, TipRanks’ AI Analyst, CNTX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and a history of cash burn), partially offset by a strong technical uptrend and positive recent corporate updates around pipeline milestones and governance. Valuation remains constrained by ongoing losses and the lack of dividend support.
To see Spark’s full report on CNTX stock, click here.
More about Context Therapeutics
Context Therapeutics Inc. is a Philadelphia-based, clinical-stage biopharmaceutical company focused on advancing T cell engaging bispecific antibodies for solid tumors. Its portfolio includes CTIM-76, a Claudin 6 x CD3 T cell engager, alongside Mesothelin x CD3 candidate CT-95 and Nectin-4 x CD3 candidate CT-202, targeting cancers with significant unmet medical need.
The company concentrates on developing innovative bispecific therapeutics aimed at harnessing the immune system to treat a range of solid tumors. By focusing on targets such as CLDN6, mesothelin and nectin-4, Context seeks to address difficult-to-treat cancers including ovarian, endometrial, lung, gastric and testicular malignancies, positioning itself within a competitive immuno-oncology landscape.
Average Trading Volume: 1,593,477
Technical Sentiment Signal: Buy
Current Market Cap: $243.5M
For a thorough assessment of CNTX stock, go to TipRanks’ Stock Analysis page.